REVB Q3 2024 Earnings — Revelation Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

REVBRevelation Biosciences, Inc.

$2M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$7,220

Operating Income

-$2M

Net Income

-$2M

EPS (Diluted)

$-13.38

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$32,095

Balance Sheet

Total Assets

$7M

Total Liabilities

$4M

Stockholders' Equity

$3M

Cash & Equivalents

$7M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$7,220	-$6,262	-15.3%
Operating Income	-$2M	-$3M	+35.3%
Net Income	-$2M	-$3M	+14.7%